Search Results for “biotechnology” – Page 6 – media

ARCH completes $3 billion fundraising! Focus on AI pharmaceuticals

ARCH Venture Partners, an American biotech investment institution, announced the completion of over $3 billion in ARCH Venture Fund XIII fundraising, aimed at supporting the establishment and development of early-stage biotech companies. The 13th fund was established following the 12th fund of $2.975 billion announced in June 2022. “After 38 years, ARCH’s investment philosophy remains the same: we bet on great science and great teams to build breakthrough companies,” said Robert Nelsen, co-founder and managing director of ARCH. “We believe that artificial intelligence and new data-driven insights into biology will help build a more preventive, curative and equitable healthcare system.” “ARCH has a long history of identifying the top forward-looking trends in life science R&D and individuals who drive truly groundbreaking scientific hypotheses,” said Keith Crandell, co-founder and managing director of ARCH. “We are very excited about the pace of innovation and efforts to understand diseases at a deeper level.” ...
- Source: drugdu
- 67
- October 11, 2024
Latest! AstraZeneca announces 10 billion yuan cooperation

On October 7, AstraZeneca and CSPC Pharmaceutical Group signed an exclusive licensing agreement, and AstraZeneca will obtain CSPC Pharmaceutical Group’s preclinical candidate small molecule drug YS2302018. The transaction amount hit a new high. According to the agreement, CSPC Pharmaceutical Group will receive an advance payment of US$100 million and is entitled to receive potential development milestone payments of up to US$370 million and potential sales milestone payments of up to US$1.55 billion, as well as tiered sales commissions calculated based on the annual net sales of the product (the total transaction amount exceeds RMB 10 billion at the current exchange rate). YS2302018 is a preclinical innovative small molecule lipoprotein (a) (Lp(a)) inhibitor used to develop new lipid-lowering therapies, as well as monotherapy or combination therapy for a variety of cardiovascular diseases, including in combination with the oral small molecule PCSK9 inhibitor AZD0780. Lpa is an important target in the field ...
- Source: drugdu
- 80
- October 10, 2024
Domestic substitution has entered the sprint period, where is the key?

As one of the hottest terms in 2024, “new quality productivity” is not only an upgrade of economic terms, but also a reflection of the process of era change, hiding the pulse of future industrial development. In many reports and documents issued by the state this year, the field of life sciences is closely linked to new quality productivity. At present, Beijing, Shanghai, Guangdong, Chongqing, Zhejiang, Jiangsu and other provinces and cities have successively issued documents to promote the development of new quality productivity and detailed implementation. At present, the field of life sciences is in a period of rapid change, showing unprecedented vitality. After returning to China after studying abroad, many outstanding scholars have greatly promoted the development of this field, especially the development of basic medical research, biotechnology innovation, biopharmaceuticals, clinical diagnosis and treatment. The development is particularly prosperous. Although the medical industry is treacherous, the rules are ...
- Source: drugdu
- 64
- October 10, 2024
Let’s go to Europe to seek gold

It is a general trend for pharmaceutical companies to go overseas, and the proposition of the times behind it is also advancing with the times. Under the new changes, how to re-examine the gold-mining places such as the United States, Europe, and Southeast Asia? Different countries and regions have different market sizes and policies and regulations. How to examine the pros and cons of the market and formulate a more suitable strategy for going overseas? Everything needs to be answered by the industry. At present, more and more signs show that pharmaceutical companies are no longer just focusing on the “fat meat” of the US market as in the past, and countries and regions such as Europe are becoming more and more important. After being hit repeatedly by the FDA, more and more PD-1s have moved to Europe and been approved for listing. Since the beginning of this year, domestic ...
- Source: drugdu
- 77
- October 10, 2024
Vietnam Medipharm Expo

Organiser：Ministry of Health of Vietnam Time：July 31 – August 2, 2025 Address：799 Đ. Nguyễn Văn Linh, Tân Phú, Quận 7, Hồ Chí Minh, Vietnam Exhibition hall：Saigon Exhibition and Convention Center (SECC) Product range: Medical Products: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, rescue equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical health products and equipment, medical institution and laboratory technology equipment, medical information and technology exchange, beauty instruments Analytical Instruments: Optical analysis instruments, mass spectrometers, spectrographs, chromatographs, spectroscopes, frequency spectrum analyzers, electrochemical analysis instruments, ray analysis instruments, gas chromatography, liquid chromatography, thermal analysis instruments, various portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, component analysis instruments, syringe analysis instruments, and other general analytical instruments Laboratory Equipment: Laboratory instruments and equipment, laboratory automation and accessories, optical equipment, microscopes, optical ...
- Source: drugdu
- 96
- October 10, 2024
Merger of two well-known pharmaceutical companies

On October 7, Jiahe Bio announced that it would acquire Yitong Pharmaceuticals by merger. The name of the merged company will be changed to Yitong Jiahe Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Yitong Jiahe”). The transaction is carried out in the form of a share swap. The price of the proposed merger will be fully settled by issuing consideration shares. After the merger is completed, the shareholders of both parties will jointly hold the equity of Yitong Jiahe, and Jiahe Bio will not have any cash expenditure. According to the listing rules, the transaction constitutes a reverse acquisition of Jiahe Bio. In the merged Yitong Jiahe, the original Yitong Pharmaceutical shareholders accounted for 77.43%, and the original Jiahe Bio shareholders accounted for 22.57%. The actual controller of Yitong Pharmaceutical will become the controlling shareholder of Yitong Jiahe. Based on the rules of Chapter 18A of the Hong Kong ...
- Source: drugdu
- 70
- October 10, 2024
The 2024 “Most Promising New Talent in Biopharmaceuticals” list has been released!

Recently, well-known industry media Endpoint News released the “Biopharma’s Most Exciting Startups in 2024” list, which includes 11 biotechnology companies. These emerging research fields include gene editing, immunotherapy, antibody conjugated drugs (ADCs), weight loss therapy, and multiple other directions. This article will introduce these 11 rising stars (listed in no particular order) to readers, based on this ranking and official information from various companies. Lifordi Immunotherapies is a biotechnology company dedicated to developing ADC therapies for the treatment of autoimmune and inflammatory diseases. Lifordi was founded in 2023 and has secured $70 million in Series A funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture, with the goal of advancing the main candidate drug LFD-200 into clinical trials and obtaining preliminary data by the end of 2025. Lifordi’s main ADC therapy LFD-200 targets myeloid cells and lymphocytes by targeting highly internalized cell surface facial mask proteins. This therapy has ...
- Source: drugdu
- 94
- October 9, 2024
What is the impact of the House of Representatives’ passage of the draft biosafety law amid the controversy on WuXi

On September 9, the House of Representatives of the United States Congress returned from a summer break and immediately scheduled a series of legislative votes, including the draft Biosafety Act (H.R. 8333). The draft biosecurity law passed the House of Representatives with 306 votes in favor and 81 votes against, but the 70% support rate made it the most divisive draft bill in the same batch, and even narrowly fell below the “bottom line” of more than two-thirds of the votes to pass the bill. The draft Biosafety Act places five companies, including WuXi AppTec and WuXi Biologics, on the list of “biotechnology companies of concern” on the grounds of “national security”, and intends to restrict the use of funds, loans or subsidies from the United States government to cooperate with these companies. Unlike previous committees that voted in small groups, this time there were several members of the House ...
- Source: drugdu
- 79
- October 6, 2024
Optimization strategy for production process of RNA targeted drugs

RNA targeted drugs are a completely new category of drugs that are completely different from small molecule drugs and antibody drugs. On the one hand, they can target mRNA, ncRNA, and other intracellular proteins through gene silencing to inhibit their expression and achieve the goal of treating diseases; On the other hand, new generation vaccines and protein replacement therapies can also be developed based on mRNA. RNA targeted drugs are undoubtedly a strategic frontier in biopharmaceutical innovation, with broad potential application scenarios in the future. The production process technology of mRNA industrialization is particularly important for the widespread application and industrialization of mRNA. Based on this, this article will focus on the optimization strategies for the production process of RNA targeted drugs. Stability chemical modification enhances drug safety and efficacy For RNA targeted drugs, chemical modification (excluding tissue targeting ligands) mainly has two basic functions: firstly, chemical modification can significantly ...
- Source: drugdu
- 102
- October 3, 2024
Seven domestic companies have completed a new round of financing, focusing on the fields of cell and gene therapy

In September, several domestic companies focused on the field of cell and gene therapy (CGT) announced progress in financing. This article will share basic information about its 7 companies based on publicly available materials. Xingsairui has successfully completed tens of millions of yuan in angel round financing On September 14th, Hangzhou Xingsai Ruizhen Biotechnology Co., Ltd. (hereinafter referred to as “Xingsai Ruizhen”) announced the completion of tens of millions of yuan in angel round financing and officially launched the angel+round financing plan! This round of financing is jointly invested by Fosun Pharma’s Rehabilitation Capital New Drug Innovation Fund and Chuangrui Investment Jiaxing Chuangyan Fund. This round of financing will be used for the continuous promotion of core pipelines and platforms, as well as the construction of the company’s team and research and development laboratories. Xingsai Ruizhen was founded in July 2022 and incubated by the New Drug Innovation ...
- Source: drugdu
- 112
- October 3, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.